Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

- PMLiVE

Amgen cholesterol antibody scores in another phase III trial

Evolocumab effective in patients who cannot take statins

- PMLiVE

J&J earnings leap on buoyant pharma sales

CEO Alex Gorsky praises "outstanding" pharmaceutical performance

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

- PMLiVE

Peacock steps down as Amgen CFO

Michael Kelly appointed acting financial head

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

- PMLiVE

J&J’s Imbruvica tops Arzerra in phase III trial

Shows improvement over GSK’s drug in haematological malignancies

- PMLiVE

Pharma slammed by MPs for withholding trial data

Follows damning Tamiflu and data access report from UK's Public Accounts Committee

- PMLiVE

Pharma clinical data sharing policy comes into effect

GSK and Sanofi among companies to announce public support of new guidelines

EU flag

MEPs agree clinical trial regulation revision

Paves way for EU trial database and simplified online applications for new studies

- PMLiVE

BIA: Political compromises could undermine EU trial reform

UK biotech body speaks out on eve of crucial committee hearing

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links